Purchase ALD-52
Discount program, second order - 5% OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy ALD-52 for sale
ALD-52, also known as 1-acetyl-LSD, is a chemical analog of lysergic acid diethylamide (LSD). It was originally discovered by Albert Hofmann in 1957 but was not widely studied until the rise in popularity of psychedelics in the 1960s. Its full effects and safety are still being researched.
ALD-52 (1-acetyl-LSD) is a chemical analog of lysergic acid diethylamide (LSD), a powerful hallucinogenic drug. It was created by Dr. Albert Hofmann, the same chemist that discovered LSD, in 1957 at Sandoz Pharmaceuticals in Switzerland. ALD-52 was not widely studied until the rise in popularity of psychedelics in the 1960s.
ALD-52 is a chemical analog of the LSD molecule, discovered in 1957 by Dr. Albert Hofmann, who went on to discover the psychedelic effects of LSD.
ALD-52 is a chemical derivative of the psychotropic drug lysergic acid diethylamide (LSD) that is an analog of the structure of diethylamide (DET).
ALD-52 is a dangerous hallucinogenic, and research chemicals are illegal in most parts of the world.
ALD-52 (1-acetyl-LSD) is a chemical analog of lysergic acid diethylamide (LSD). Albert Hofmann originally discovered it in 1957, but it wasn't until the rise in popularity of psychedelics in the 1960s that ALD-52 began to be studied seriously. The compound is structurally similar to LSD and acts on the same serotonin receptors, with similar hallucinogenic effects.
ALD-52 is a chemical analog of lysergic acid diethylamide (LSD). It was originally discovered by Albert Hofmann in 1957 but was not widely studied until the rise in popularity of psychedelics in the 1960s. ALD-52 has similar effects to LSD when administered, including hallucinogenic and entheogenic effects, though it is generally considered to be 20-30% less potent than LSD on average.
ALD-52 is a chemical analog of LSD. It was originally discovered in 1957 by Albert Hofmann but was not widely studied until the popularity of psychedelics in the '60s. ALD-52 has similar effects to LSD, hallucinogenic and entheogenic, although it is 20-30% less potent than LSD on average.
ALD-52 or N-Acetyl-LSD is the acetate ester of lysergic acid diethylamide (LSD). Albert Hofmann first synthesized it in the 1950s. It is similar to LSD chemically and shares part of its structure with it.
ALD-52 is a psychedelic substance of the lysergamide class. It is described by Alexander Shulgin in the book TiHKAL and received its name as an acronym of his initials and the chemical name of the molecule, lysergic acid diethylamide.
ALD-52 is a hallucinogenic drug that changes perception, mood, and awareness.
ALD-52 is a psychedelic drug.
ALD-52, also known as 1-acetyl-LSD, is a chemical analog of lysergic acid diethylamide (LSD). It was originally discovered by Albert Hofmann in 1957 but was not widely studied until the rise in popularity of psychedelics in the 1960s. ALD-52 can be either white or off-white and has a very subtle scent with a slightly pungent odor when vaporized.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
200g $690
1kg $1890
1kg $1690
1kg $1590
100mg $840
500g $1390
out of stock
1kg $1590
500g $1080
1kg $1590
out of stock
out of stock